S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ERNA · Ernexa Therapeutics Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Ernexa Therapeutics Inc (ERNA)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$2.13
+0.22
(+11.78%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$2.13
$2.13
$2.15
52-WEEK RANGE
$2.13
$1.84
$71.50
What's happening
- ERNA is up 11.78% today, trading at $2.13. — Live quote
- It's trading within 3% of its 52-week low ($1.84). (Finnhub fundamentals)
- Volume today (726) is well below its 3-month average of 351,440. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-3.40 actual vs. $-3.37 estimated (-1.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 4
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ERNA
-92.97%
vs S&P 500
-106.34%
1-YEAR RETURN
ERNA
-93.02%
vs S&P 500
-108.19%
6-MONTH RETURN
ERNA
-59.42%
3-MONTH RETURN
ERNA
-52.58%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-3.40
Est. $-3.37
MISS -1.0%
2023-10-26 (Q3 2023)
$-1.03
Est. $—
2022-10-26 (Q3 2022)
$-933.75
Est. $-841.50
MISS -11.0%
2022-07-26 (Q2 2022)
$-450.00
Est. $-994.50
BEAT +54.8%
Valuation Measures & Ratios
Enterprise Value4-$1.3M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)6.00
Price / Book72.42
EV4 / Revenue-2.21
EV4 / EBITDA—
Profit Margin-7720.96%
Operating Margin-6600.34%
Return on Equity (ROE8)-169.40%
Return on Assets (ROA9)-228.54%
Avg Volume (3M)351,440
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $8.0M | $4.0M | $242.9M | $9.8M | $10.3M |
| P/E | -0.57 | -0.22 | -6.20 | -0.23 | -0.22 |
| Price/Book | 2.49 | 0.58 | 68.03 | 2.21 | -1.73 |
| EV/EBITDA | -0.56 | -0.31 | -25.85 | — | — |
| ROE | -434.19% | -263.70% | -1097.62% | -978.26% | 789.61% |
| ROA | -220.02% | -171.55% | -634.88% | -573.23% | -928.68% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short19,725
Change from Prior Settlement+37.35%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -7721.0%. Finnhub fundamentals ↗
- Trailing 52-week price return is -93.0%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ERNA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $487.0K | $47.0K | $47.0K |
| Gross profit | — | — | — | — | — | $547.0K | -$48.0K | -$14.0K |
| Operating income | -$4.1M | -$5.6M | -$2.0M | -$2.5M | -$2.7M | -$2.3M | -$4.9M | -$5.8M |
| Net income | -$4.0M | -$5.5M | -$1.2M | -$3.1M | -$8.2M | -$26.6M | -$5.5M | -$6.6M |
| EPS (diluted) | $-3.40 | $-6.95 | $-0.15 | $-15.19 | $-57.76 | $-73.70 | $-15.34 | $-1.23 |
| EPS (basic) | $-3.40 | $-6.95 | $-0.15 | $-15.19 | $-57.76 | $-73.70 | $-15.34 | $-1.23 |
| Operating margin | — | — | — | — | — | -$464 | -$10.5K | -$12.3K |
| Net margin | — | — | — | — | — | -$5.5K | -$11.8K | -$14.1K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $6.3M | $10.5M | $5.8M | $6.2M | $7.6M | $5.1M | $5.3M | $7.7M |
| Total liabilities | $3.1M | $3.7M | $3.4M | $2.6M | $3.1M | $11.0M | $3.6M | $53.1M |
| Stockholders' equity | $3.2M | $6.9M | $2.4M | $3.6M | $4.4M | -$6.0M | $1.7M | -$45.4M |
| Total current assets | $5.9M | $10.0M | $3.1M | $3.4M | $4.8M | $2.2M | $2.4M | $4.7M |
| Total current liabilities | $2.9M | $3.5M | $3.1M | $2.1M | $2.7M | $10.4M | $2.9M | $10.0M |
| Cash & equivalents | — | — | — | — | $4.3M | $1.9M | $1.7M | $4.3M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $82.0K | $88.0K | $94.0K | $92.0K | $50.0K | $67.0K | $85.0K | $105.0K |
| Goodwill | — | — | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $25.0K | $110.0K | $110.0K | $116.0K | $117.0K | $118.0K | $118.0K | $120.0K |
| Accounts payable | $1.4M | $1.3M | $1.1M | $958.0K | $1.3M | $1.3M | $1.7M | $2.2M |
| Accrued liabilities | $1.0M | $1.5M | $898.0K | $859.0K | $938.0K | $1.4M | $1.0M | $1.2M |
| Deferred revenue (current) | — | — | — | — | — | $5.3M | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | $124.0K | $218.0K | $83.0K | $63.0K | $125.0K | — | — | $113.0K |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $1.0K | $1.0K | $43.0K | $112.0K | $113.0K | $111.0K | $111.0K | $84.0K |
| Common stock & paid-in capital | $6.0K | $6.0K | $2.0K | $39.0K | $37.0K | $262.0K | $17.0K | $27.0K |
| Retained earnings | -$255.2M | -$251.1M | -$245.6M | -$244.1M | -$242.9M | -$239.7M | -$231.5M | -$225.8M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.2M | -$2.3M | -$1.1M | -$1.3M | -$2.5M | -$2.1M | -$3.5M | -$6.3M |
| Investing cash flow | -$3.0K | -$2.0K | -$15.0K | -$22.0K | — | — | $0 | -$19.0K |
| Financing cash flow | $6.0K | $9.6M | $0 | $26.0K | $4.9M | $2.3M | $1.0M | $3.9M |
| Free cash flow | -$4.2M | -$2.3M | -$1.2M | -$1.3M | — | — | -$3.5M | -$6.3M |
| Capital expenditures | $3.0K | $2.0K | $15.0K | $22.0K | — | — | $0 | $19.0K |
| Depreciation & amortization | $9.0K | $8.0K | $13.0K | $17.0K | $17.0K | $18.0K | $19.0K | $37.0K |
| Share-based compensation | $320.0K | $309.0K | $333.0K | $293.0K | $368.0K | $502.0K | $410.0K | $405.0K |
| Deferred income taxes | — | — | -$48.0K | — | — | — | $27.0K | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | $582.0K | $68.0K | $0 | — |
| Gross profit | — | $486.0K | -$168.0K | $0 | — |
| Operating income | -$9.3M | -$15.7M | -$21.1M | -$33.2M | -$113.7M |
| Net income | -$14.1M | -$44.5M | -$21.7M | -$24.6M | -$122.5M |
| EPS (diluted) | $-2.24 | $-48.96 | $-4.08 | $-8.06 | $-56.61 |
| EPS (basic) | $-2.24 | $-48.96 | $-4.08 | $-8.06 | $-56.61 |
| Operating margin | — | -$2.7K | -$31.1K | — | — |
| Net margin | — | -$7.7K | -$31.9K | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $5.8M | $5.3M | $49.1M | $22.3M | $31.5M |
| Total liabilities | $3.4M | $3.6M | $46.9M | $10.2M | $6.0M |
| Stockholders' equity | $2.4M | $1.7M | $2.2M | $12.1M | $25.5M |
| Total current assets | $3.1M | $2.4M | $9.6M | $13.7M | $18.8M |
| Total current liabilities | $3.1M | $2.9M | $6.6M | $7.7M | $3.7M |
| Cash & equivalents | — | $1.7M | $7.6M | $11.4M | $17.0M |
| Accounts receivable | — | — | — | — | $684.0K |
| Property, plant & equipment | $94.0K | $85.0K | $493.0K | $236.0K | $670.0K |
| Goodwill | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | $110.0K | $118.0K | $120.0K | $1.1M | $488.0K |
| Accounts payable | $1.1M | $1.7M | $1.1M | $1.6M | $1.8M |
| Accrued liabilities | $898.0K | $1.0M | $1.9M | $3.6M | $1.2M |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | — | — | — | — | — |
| Other current liabilities | $83.0K | — | — | $363.0K | $247.0K |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | $43.0K | $111.0K | $84.0K | $94.0K | $48.0K |
| Common stock & paid-in capital | $39.0K | $17.0K | $27.0K | $26.0K | $13.0K |
| Retained earnings | -$245.6M | -$231.5M | -$187.0M | -$165.3M | -$140.7M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$7.0M | -$15.8M | -$20.4M | -$21.0M | -$23.5M |
| Investing cash flow | -$37.0K | -$365.0K | -$19.0K | -$47.0K | -$22.7M |
| Financing cash flow | $7.2M | $6.3M | $16.6M | $19.6M | $61.6M |
| Free cash flow | -$7.1M | -$16.2M | -$20.4M | -$21.3M | -$23.6M |
| Capital expenditures | $37.0K | $369.0K | $19.0K | $297.0K | $154.0K |
| Depreciation & amortization | $65.0K | $139.0K | $84.0K | $161.0K | $117.0K |
| Share-based compensation | $1.5M | $1.5M | $1.2M | $2.9M | $5.2M |
| Deferred income taxes | -$48.0K | $27.0K | -$4.0K | -$8.6M | -$7.3M |
| Change in accounts receivable | — | — | — | — | $659.0K |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
| Tax withholding on stock comp | — | — | $0 | $5.0K | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ERNA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
No 13F institutional ownership reported for this symbol.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-06-21 to 2026-02-10
Recent transactions
- Most recent: Cherington Charles (10% owner) — Open market purchase of 4,000,000 shares on 2026-02-10.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Cherington Charles | 10% owner | Open market purchase | 2026-02-10 | 4,000,000 |
| Gurrola Sandra M | Sr. VP of Finance | Option exercise | 2025-06-21 | 30 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-02-10 | Cherington Charles | 10% owner | Open market purchase | 4,000,000 | $0.50 |
| 2025-06-21 | Gurrola Sandra M | Sr. VP of Finance | Option exercise | 30 | — |
| 2025-06-09 | Cherington Charles | 10% owner | Open market purchase | 21,241,163 | $0.10 |
| 2025-04-02 | Cherington Charles | 10% owner | Open market purchase | 3,768,397 | $0.10 |
| 2024-10-29 | Cherington Charles | 10% owner | Open market purchase | 261,756 | — |
| 2024-10-29 | Cherington Charles | 10% owner | Open market purchase | 4,768,783 | — |
| 2024-10-29 | Cherington Charles | 10% owner | Open market purchase | 1,237,762 | — |
| 2024-10-29 | Cherington Charles | 10% owner | Open market purchase | 5,420,823 | — |
| 2024-10-29 | Cherington Charles | 10% owner | Open market purchase | 1,562,988 | — |
| 2024-10-29 | Cherington Charles | 10% owner | Derivative conversion | 2,819,546 | $0.50 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:35 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-09-16 | 8-K | 2026-09-16 | View on SEC.gov → |
| 2026-09-16 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 8-K | 2026-07-02 | View on SEC.gov → |
| 2026-07-02 | 8-K | 2026-07-01 | View on SEC.gov → |
Recent news
Headlines about ERNA (Ernexa Therapeutics Inc.). Links open the publisher — we don’t host full articles.
-
SULLY ERNA Confirms New GODSMACK Music Will 'Happen At Some Point Next Year': 'I'm Very Curious Myself Where It'll Go'
BLABBERMOUTH.NET · 2026-10-21 -
ERNAW Warrants Hold Flat at $0.03 as Ernexa Therapeutics Buyers and Sellers Reach Equilibrium - Golden Cross
https://www.siam.in/ · 2026-10-17 -
ERNA 8-K & SEC Filings
Yahoo Finance · 2026-10-15 -
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Yahoo · 2026-10-12 -
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Yahoo Finance · 2026-10-06 -
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
Yahoo Finance · 2026-10-01 -
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Yahoo Finance · 2026-09-30 -
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
Yahoo Finance · 2026-09-29
No headlines in this category right now — try “All”.